Key Art Banner

Checklist: A New Weapon Tackles A Tough Disease

Genentech innovation TECENTRIQ offers a new treatment option that can provide a clinically meaningful survival benefit for people with lung cancer.
Posted on Jan 22, 2020 | 10:30am
Brough to you by Watch!

Pharmaceutical giant Genentech has just garnered FDA approval for TECENTRIQ to be used in combination with chemotherapy as a first line of treatment for adults with metastatic non-squamous non-small cell lung cancers--which, according to the American Cancer Society, account for 80-85% of all lung cancers. The go-ahead was based on a Phase III randomized study of 724 people, which compared the results of those given TECENTRIQ plus chemotherapy to the outcomes of those given chemotherapy alone. 

The study determined that participants given the TECENTRIQ and chemo combination lived significantly longer and had a significantly reduced risk of disease progression, as compared to their chemotherapy-only counterparts. "We are pleased to offer this TECENTRIQ-based combination as a new treatment option," says Genentech's chief medical officer and head of global product development Levi Garraway, M.D., Ph.D. "Today's approval offers another opportunity to help prolong the lives of people with this type of disease." 

Talk to your oncologist to see if TECENTRIQ is right for you. For product information, prescribing information, medication guide, and possible side effects, visit tecentriq.com.

Photo Credit: utah778/Getty Images.